KRYS - NASDAQ
Krystal Biotech, Inc.
$301.82
+0.74%Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
At a Glance
Live SnapshotKrystal Biotech, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
Krystal Biotech, Inc. Cash Flow Statement
KRYS • NASDAQ
| Krystal Biotech, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||
204.8M | 89.2M | 10.9M | -140M | -69.6M | -32.2M | -19.1M | -10.9M | -7.9M | -1.2M | |
6.6M | 6.7M | 5M | 4.1M | 2.8M | 1.9M | 748K | 141K | 23K | 2K | |
-22.8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
54.5M | 49.1M | 39.9M | 33.2M | 15.3M | 3.3M | 1.2M | 792K | 246K | 33K | |
-5.8M | -7.1M | -106.8M | -690K | 1.5M | 33K | 67K | 962K | 3.3M | 7K | |
(0.0) | (5.7M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-36.4M | -14.5M | -37.9M | 2.8M | 2.1M | 928K | -1.7M | 511K | 498K | -203K | |
200.9M | 123.4M | -88.8M | -100.6M | -47.9M | -26.1M | -18.7M | -9.4M | -3.9M | -1.3M | |
INVESTING ACTIVITIES | ||||||||||
-12M | -4.2M | -11.8M | -53M | -68.3M | -14.8M | -6.4M | -2.2M | -210K | -15K | |
(435K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-422.5M | -457.7M | -508.8M | -318.8M | -190.5M | -3.2M | -9.1M | -8.1M | (0.0) | (0.0) | |
375.6M | 298.5M | 503.2M | 257.7M | 32M | 6.9M | 10.5M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 100M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-58.4M | -163.4M | (82.6M) | -114.1M | -226.8M | -11.2M | -5M | -10.3M | -210K | -15K | |
FINANCING ACTIVITIES | ||||||||||
22.7M | 32.4M | 203.5M | 36M | 355.6M | 118M | 107.5M | 73.8M | 42.5M | 100K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2.3M | 1.8M | |
-14M | -5.4M | -749K | -649K | -8M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
8.7M | 27M | 202.8M | 35.3M | 347.7M | 118M | 107.5M | 73.8M | 51.8M | 3.2M | |
CASH FLOW SUMMARY | ||||||||||
286K | -458K | -156K | -41K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
151.4M | -13.5M | 196.4M | -179.3M | 73M | 80.8M | 83.8M | 54.1M | 47.7M | 1.9M | |
344.9M | 358.3M | 161.9M | 341.2M | 268.3M | 187.5M | 103.7M | 49.6M | 1.9M | 0.0 | |
496.3M | 344.9M | 358.3M | 161.9M | 341.2M | 268.3M | 187.5M | 103.7M | 49.6M | 1.9M | |
188.9M | 119.2M | -100.6M | -153.5M | -116.3M | -40.9M | -25.1M | -11.7M | -4.1M | -1.3M |
SEC Filings
KRYS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 20, 2026 | May 15, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 03, 2026 | April 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 17, 2026 | February 17, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 23, 2025 | December 23, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 |
Related Guides
Continue your KRYS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.